HCM
EIGR

Highbridge Capital Management’s Eiger BioPharmaceuticals, Inc. EIGR Stock Holding History

Highbridge Capital Management’s Portfolio EIGR Stock Details EIGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-4,702
Closed -$1.72M – 935
2018
Q2 		$1.72M Sell
4,702
-1,465
-24% -$522K 0.03% 400
2018
Q1 		$1.82M Hold
6,167
– – 0.03% 450
2017
Q4 		$2.58M Buy
+6,167
New +$2.2M 0.05% 351

Other funds holding EIGR

VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
IVM
InterWest Venture Management San Francisco, California $20.6M AUM 48.5% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Highbridge Capital Management's EIGR Position: Q3 2018 in Review

Highbridge Capital Management sold out of Eiger BioPharmaceuticals, Inc. (EIGR) in Q3 2018, closing a stake of 4,702 shares — an estimated $1.72M sold.

Highbridge Capital Management first reported a position in EIGR in Q4 2017 and held it in 3 quarters. The position peaked at $2.58M in Q4 2017. 53 funds tracked by Wall St. Rank hold EIGR as of Q3 2018.

  • Highbridge Capital Management reported no remaining Eiger BioPharmaceuticals, Inc. position as of Q3 2018 after selling out during the quarter.
  • Highbridge Capital Management sold 4,702 Eiger BioPharmaceuticals, Inc. shares in Q3 2018, an estimated $1.72M.
  • Highbridge Capital Management first reported a position in Eiger BioPharmaceuticals, Inc. in Q4 2017 and held it in 3 quarters.
  • Highbridge Capital Management's Eiger BioPharmaceuticals, Inc. position peaked at $2.58M in Q4 2017.
  • 53 funds tracked by Wall St. Rank held Eiger BioPharmaceuticals, Inc. as of Q3 2018.

Based on Highbridge Capital Management's 13F filing for Q3 2018, filed 13 Nov 2018.